Myriad Genetics, Inc. (MYGN) Tops Q3 EPS by 3c; Boosts FY14 Outlook
Get Alerts MYGN Hot Sheet
Price: $17.98 -3.49%
Financial Fact:
Companion diagnostic services: 12.4M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Financial Fact:
Companion diagnostic services: 12.4M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
Myriad Genetics, Inc. (NASDAQ: MYGN) reported Q3 EPS of $0.48, $0.03 better than the analyst estimate of $0.45. Revenue for the quarter came in at $176.2 million versus the consensus estimate of $175.23 million.
Myriad Genetics, Inc. sees FY2014 EPS of $2.37 - $2.40, versus prior guidance of $2.09 - $2.12 and the consensus of $2.19. Myriad Genetics, Inc. sees FY2014 revenue of $770 - $775 million, versus prior guidance of $740 - $750 million and the consensus of $764.01 million.
For earnings history and earnings-related data on Myriad Genetics, Inc. (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- Alphabet (GOOG) Tops Q1 EPS by 38c
- Phillips Edison & Company (PECO) Reports In-Line Q1 EPS, provides guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!